NICE does not recommend Lynparza as maintenance treatment for ovarian cancer. AstraZeneca + Merck Inc.
The National Institute for Health and Care Excellence (NICE) in draft guidance, has recommended against expanding coverage of Lynparza as an ovarian cancer treatment for maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that is in response to platinum-based chemotherapy in adults. The recommendation relates to the tablet formulation of olaparib.
NICE found the clinical profile and pricing of the drug to exceed its cost effectiveness range when considering the drug as a maintenance treatment
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.